Biases in the identification of risk factor thresholds and J-curves

American Journal of Epidemiology

Volumn 166, Issue 7, 2007, Pages 824-831

  Marschner, Ian C ^a,b   Simes, R John ^b   Keech, Anthony ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bias (epidemiology); Cardiovascular diseases; Confounding factors (epidemiology); Effect modifiers (epidemiology); Incidence; Primary prevention; Risk factors

Indexed keywords

CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DISEASE INCIDENCE; EPIDEMIOLOGY; RISK FACTOR;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONFOUNDING VARIABLE; CONTROLLED STUDY; HIGH RISK POPULATION; HUMAN; J CURVE; LINEAR SYSTEM; MAJOR CLINICAL STUDY; NONLINEAR SYSTEM; PLOTS AND CURVES; PROSPECTIVE STUDY; RANDOMIZATION; RISK FACTOR; SECONDARY PREVENTION; SIMULATION; SYSTEMATIC ERROR; THEORETICAL STUDY;

AUSTRALIA; BIAS (EPIDEMIOLOGY); CARDIOVASCULAR DISEASES; CONFOUNDING FACTORS (EPIDEMIOLOGY); EFFECT MODIFIERS (EPIDEMIOLOGY); HUMANS; INCIDENCE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS;

EID: 34548787388     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwm145     Document Type: Article

References (26)

1. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ 2002;324:1570-6.
2. Jackson R, Lawes CMM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005;365:434-41.
3. Saver JL. Recent major changes in evidence-based approaches to treating high blood pressure. Rev Neurol Dis 2004;1:47-9.
4. Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 1998;97:1466-52.
5. D'Agostino RB, Belanger AJ, Kannel WB, et al. Relation of low diastolic blood pressure to coronary heart disease death in the presence of myocardial infarction: the Framingham Study. BMJ 1991;303:385-9.
6. Irie K, Yamaguchi T, Minematsu K, et al. The J-curve phenomenon in stroke recurrence. Stroke 1993;24:1844-9.
7. Port S, Demer L, Jenrich R, et al. Systolic blood pressure and mortality. Lancet 2000;355:175-80.
8. Matsuzaki M, Kita T, Mabuchi H, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 2002;66:1087-95.
9. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
10. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
11. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45.
12. Cannon CP. The IDEAL cholesterol: lower is better. JAMA 2005;294:2492-4.
13. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
14. Law MR, Wald NJ, Thompson SG. By how much and how quickly does the reduction in serum cholesterol concentration lower the risk of ischaemic heart disease? BMJ 1994;308:367-73.
15. Biagent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
16. Spearman C. The proof and measurement of association between two things. Am J Psychol 1904;15:72-101.
17. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999;150:341-53.
18. McMahon S, Peto R, Collins R, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.
19. Rosner B, Spiegelman D, Willett WC. Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. Am J Epidemiol 1992;136:1400-13.
20. Carroll RJ, Ruppert D, Stefanski L. Measurement error in non-linear models. New York, NY: Wiley, 1995.
21. McCullagh P, Nelder JA. Generalized linear models. New York, NY: Chapman and Hall, 1989.
22. Marschner IC, Colquhoun D, Simes RJ, et al. Long-term risk stratification for survivors of acute coronary syndromes: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. J Am Coll Cardiol 2001;38:56-63.
23. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
24. Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid level and clinical outcomes in the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002;105:1162-9.
25. Lawes CM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. Asia Pacific Cohort Studies Collaboration. J Hypertens 2003;21:707-16.
26. Lawes CMM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews. Stroke 2004;35:776-85.